CYTK - Why Is Heart Disease Focused Cytokinetics Stock Trading Higher Today? | Benzinga
Cytokinetics Incorporated (NASDAQ: CYTK) released topline results from the SEQUOIA-HCM Phase 3 trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Hypertrophic cardiomyopathy typically affects the muscular wall (septum) between the two bottom chambers of the heart (ventricles).
The thickened wall might block blood flow out of the heart.
Also Read: Potential Takeover In ...